Loading...
XSHE002287
Market cap1.49bUSD
Jan 15, Last price  
20.53CNY
1D
-0.24%
1Q
-11.32%
Jan 2017
-39.81%
IPO
22.35%
Name

Tibet Cheezheng Tibetan Med Co Ltd

Chart & Performance

D1W1MN
XSHE:002287 chart
P/E
18.76
P/S
5.42
EPS
1.09
Div Yield, %
2.02%
Shrs. gr., 5y
0.11%
Rev. gr., 5y
10.63%
Revenues
2.01b
-1.69%
267,916,235339,273,207413,480,079469,298,025523,645,170789,225,148934,274,709969,466,771950,105,636994,727,830968,353,9431,053,150,8981,213,209,0641,402,676,9041,476,213,8031,770,485,9892,044,789,3402,010,312,806
Net income
581m
+22.99%
105,950,265115,840,374135,795,272160,812,032170,461,486170,718,429190,179,498213,372,739237,534,133264,911,033289,861,633300,842,399318,767,001364,254,312403,961,153715,876,201472,542,429581,198,850
CFO
693m
+142.72%
38,498,79091,434,93465,926,967175,577,47396,905,6550169,672,206198,479,275310,947,521257,812,883389,201,594229,827,826499,396,887405,951,978238,651,6011,034,917,529285,686,729693,405,083
Dividend
Jul 04, 20240.48 CNY/sh
Earnings
May 09, 2025

Profile

Tibet Cheezheng Tibetan Medicine Co., Ltd. together with its subsidiaries, engages in the research, development, production, and sale of Tibetan medicine in China. It provides drug products in the areas of cardiovascular, respiratory, digestive, urinary and reproductive system, nervous system, musculoskeletal system, and gynecological disorders. The company was founded in 1995 and is based in Nyingchi, China. Tibet Cheezheng Tibetan Medicine Co., Ltd. operates as a subsidiary of Gansu Qizheng Industry Group Co., Ltd.
URL
http://www.cheezheng.com.cn/
IPO date
Aug 28, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,010,313
-1.69%
2,044,789
15.49%
Cost of revenue
1,101,282
1,365,075
Unusual Expense (Income)
NOPBT
909,031
679,715
NOPBT Margin
45.22%
33.24%
Operating Taxes
65,235
49,694
Tax Rate
7.18%
7.31%
NOPAT
843,796
630,021
Net income
581,199
22.99%
472,542
-33.99%
Dividends
(220,047)
(312,783)
Dividend yield
1.85%
2.58%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
451,518
762,306
Long-term debt
1,075,267
939,294
Deferred revenue
191,305
167,039
Other long-term liabilities
193,905
2,600
Net debt
(1,882,835)
(275,262)
Cash flow
Cash from operating activities
693,405
285,687
CAPEX
(234,814)
Cash from investing activities
(310,591)
Cash from financing activities
(431,897)
FCF
868,872
77,836
Balance
Cash
2,366,480
1,976,861
Long term investments
1,043,140
Excess cash
3,309,105
1,874,622
Stockholders' equity
2,821,400
2,933,019
Invested Capital
2,662,439
3,317,473
ROIC
28.22%
19.85%
ROCE
16.51%
13.00%
EV
Common stock shares outstanding
530,097
530,224
Price
22.49
-1.58%
22.85
-25.23%
Market cap
11,921,892
-1.60%
12,115,613
-25.09%
EV
10,088,872
11,891,991
EBITDA
1,002,271
762,902
EV/EBITDA
10.07
15.59
Interest
63,070
56,423
Interest/NOPBT
6.94%
8.30%